Menu Search
Equities

Prophase Labs Inc

QGY:BER

Prophase Labs Inc

Actions
  • Price (EUR)4.82
  • Today's Change-0.08 / -1.63%
  • Shares traded220.00
  • 1 Year change-43.95%
  • Beta--
Data delayed at least 15 minutes, as of May 24 2024 07:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.

  • Revenue in USD (TTM)28.72m
  • Net income in USD-23.60m
  • Incorporated2015
  • Employees113.00
  • Location
    Prophase Labs Inc711 STEWART AVE, SUITE 200, GARDEN CITYNEW YORK 11530United StatesUSA
  • Phone+1 (215) 345-0919
  • Websitehttps://www.prophaselabs.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.